Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...

Researchers at National Taiwan University have unveiled an innovative diagnostic tool that significantly improves the speed ...

R-708-5p is a stress-regulated microRNA and a potential biomarker for the differential diagnosis of human mood disorders.

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

Standardizing data collection in ME/CFS research through Common Data Elements is a crucial step toward improving diagnosis, ...

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...

Students reacted to a California bill that, if passed, would make it illegal for companies to sell such products to shoppers under 18 years old. By The Learning Network We invite students to ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.

Digital adherence technologies did not reduce poor treatment outcomes in the four countries investigated. The use of digital adherence technologies should be based on careful review of additional data ...